Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins.

Kums J, Nelke J, Rüth B, Schäfer V, Siegmund D, Wajant H.

MAbs. 2017 Apr;9(3):506-520. doi: 10.1080/19420862.2016.1274844. Epub 2017 Jan 17.

2.

Generation and Application of Bioluminescent CD95 Ligand Fusion Proteins.

Lang I, Kums J, Wajant H.

Methods Mol Biol. 2017;1557:63-77. doi: 10.1007/978-1-4939-6780-3_7.

PMID:
28078583
3.

Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis.

Siegmund D, Kums J, Ehrenschwender M, Wajant H.

Cell Death Dis. 2016 Sep 22;7(9):e2375. doi: 10.1038/cddis.2016.285.

4.

Comparison of GreenLight laser and transurethral resection of the prostate baseline characteristics and outcomes: lessons learned from the Clinical Research Office of the Endourological Society GreenLight Laser Study.

Muir G, Klecka J, Culkin DJ, Barusso GH, Kums J, Brunken C, Eure G, Rioja Sanz C, Gomez Sancha F, Yildiz MM, de la Rosette JJ; CROES GLS Study Group.

Minerva Urol Nefrol. 2017 Jun;69(3):285-292. doi: 10.23736/S0393-2249.16.02721-1. Epub 2016 Oct 5.

5.

Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion.

Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, Amich J, Vaeth M, Kuen J, Holtappels R, Podlech J, Mottok A, Kraus S, Jordán-Garrote AL, Bäuerlein CA, Brede C, Ribechini E, Fick A, Seher A, Polz J, Ottmüller KJ, Baker J, Nishikii H, Ritz M, Mattenheimer K, Schwinn S, Winter T, Schäfer V, Krappmann S, Einsele H, Müller TD, Reddehase MJ, Lutz MB, Männel DN, Berberich-Siebelt F, Wajant H, Beilhack A.

J Exp Med. 2016 Aug 22;213(9):1881-900. doi: 10.1084/jem.20151563. Epub 2016 Aug 15.

6.

Treatment and outcome of fibroepithelial ureteral polyps: A systematic literature review.

Ludwig DJ, Buddingh KT, Kums JJ, Kropman RF, Roshani H, Hirdes WH.

Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E631-7. doi: 10.5489/cuaj.2878. Epub 2015 Sep 9. Review.

7.

Percutaneous nephrolithotomy in children in different age groups: data from the Clinical Research Office of the Endourological Society (CROES) Percutaneous Nephrolithotomy Global Study.

Guven S, Frattini A, Onal B, Desai M, Montanari E, Kums J, Garofalo M, de la Rosette J; CROES PCNL Study Group.

BJU Int. 2013 Jan;111(1):148-56. doi: 10.1111/j.1464-410X.2012.11239.x. Epub 2012 May 11.

8.

Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.

Hendricksen K, Witjes WP, Idema JG, Kums JJ, van Vierssen Trip OB, de Bruin MJ, Vergunst H, Caris CT, Janzing-Pastors MH, Witjes JA.

Eur Urol. 2008 May;53(5):984-91. doi: 10.1016/j.eururo.2007.12.033. Epub 2007 Dec 27.

PMID:
18248876
9.

Treatment for extended-mid and distal ureteral stones: SWL or ureteroscopy? Results of a multicenter study.

Hendrikx AJ, Strijbos WE, de Knijff DW, Kums JJ, Doesburg WH, Lemmens WA.

J Endourol. 1999 Dec;13(10):727-33.

PMID:
10646679
10.

A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer.

Debruyne FM, Dijkman GA, Lee DC, Witjes WP, del Moral F, Karthaus HF, van der Mejden AP, Plasman JW, Pull HC, Kums JJ, Idema JG, Hoefakker JW, Heijbroek RP, Kil PJ, Khoe GS.

J Urol. 1996 Apr;155(4):1352-4.

PMID:
8632572
11.

A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.

Dijkman GA, del Moral PF, Plasman JW, Kums JJ, Delaere KP, Debruyne FM, Hutchinson FJ, Furr BJ.

J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):933-6.

PMID:
2149507
12.

Kock pouch urinary diversion: follow-up by ultrasound.

Kruyt RH, Kums JJ.

Br J Radiol. 1988 Sep;61(729):811-6.

PMID:
3052684
13.

Signet-ring cell carcinoma of the bladder and the prostate. Report of 4 cases.

Kums JJ, van Helsdingen PJ.

Urol Int. 1985;40(2):116-9.

PMID:
2986333

Supplemental Content

Support Center